07/31/2022
Dr. Reddy’s debuts generic Velcade
Velcade is used to treat adults with multiple myeloma, a cancer of the plasma cells. It also is used to treat adults with mantle cell lymphoma, a cancer of the lymph nodes.
Dr. Reddy’s is introducing bortezomib for injection 3.5 mg, the generic of Takeda’s Velcade.
Velcade is used to treat adults with multiple myeloma, a cancer of the plasma cells. It also is used to treat adults with mantle cell lymphoma, a cancer of the lymph nodes.
[Read more: Dr. Reddy's intros generic Revlimid in Canada]
The Velcade brand and generic had a market value of approximately $1.2 billion for the most recent 12 months ending in May 2022, according to IQVIA.
Dr. Reddy’s bortezomib for injection is supplied in a 3.5 mg per 10 ml single-dose vial presentation for subcutaneous or intravenous use.q[Read more: Dr. Reddy's unveils generic BiCNU]